1. Home
  2. Products
  3. Customized ADCs
  4. TACSTD2
  5. Anti-TACSTD2-Mc-VC-MMAD ADC-2

Anti-TACSTD2-Mc-VC-MMAD ADC-2 (CAT#: ADC-W-570)

This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone C16) conjugated via a Mc-VC linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAD binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • C16
  • Name
  • TACSTD2
  • Alternative Names
  • TACSTD2; tumor-associated calcium signal transducer 2; EGP1; GP50; M1S1; EGP-1; TROP2; GA7331; GA733-1; epithelial glycoprotein-1; cell surface glycoprotein TROP2; cell surface glycoprotein Trop-2; pancreatic carcinoma marker protein GA7331; pancreatic ca
  • Target Entrez Gene ID
  • 4070
  • Overview
  • This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals. Mutations of this gene have been associated with gelatinous drop-like corneal dystrophy.
  • Overview
  • Anti-TACSTD2 Antibody, clone # C16
  • Clone #
  • C16
  • Species Reactivity
  • Human
  • Name
  • Mc-VC (maleimidocaproyl-valine-alanine)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
  • Name
  • MMAD (monomethyl auristatin D)
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-570. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-568 Anti-TACSTD2-VC-MMAD ADC-2 VC (valine-citrulline) MMAD (monomethyl auristatin D)
ADC-W-539 Anti-TACSTD2-PEG6-Aur3377 ADC-2 Amino-PEG6-based linker Aur3377
ADC-W-563 Anti-TACSTD2-VC-PABC-Aur0101 ADC-2 VC-PABC (valine-citrulline-p-aminobenzylcarbamate) Aur0101
ADC-W-538 Anti-TACSTD2-PEG6-MMAD ADC-2 Amino-PEG6-based linker MMAD (monomethyl auristatin D)
ADC-W-292 Anti-TACSTD2-PEG6-MMAD ADC-1 PEG6 ((Propylene Glycol)-6-propionyl) MMAD (monomethyl auristatin D)
CAT# Product Name Linker Payload
ADC-W-492 Anti-CD33-Mc-VC-SGD-1882 ADC-7 mc-VC (maleimidocaproyl-valine-alanine) SGD-1882
CAT# Product Name Linker Payload
ADC-W-538 Anti-TACSTD2-PEG6-MMAD ADC-2 Amino-PEG6-based linker MMAD (monomethyl auristatin D)
ADC-W-568 Anti-TACSTD2-VC-MMAD ADC-2 VC (valine-citrulline) MMAD (monomethyl auristatin D)
ADC-W-633 Anti-ERBB2 (trastuzumab)-AcLysGly-MMAD ADC AcLysGly MMAD (monomethyl auristatin D)
ADC-W-631 Anti-ERBB2 (trastuzumab)-AcLys-VC-PABC-MMAD ADC AcLys-VC-PABC (Acetyl-lysine-valine-citrulline-p-aminobenzyloxycarbonyl) MMAD (monomethyl auristatin D)
ADC-W-167 Anti-TPBG-VC-MMAD ADC-11 VC (valine-citrulline) MMAD (monomethyl auristatin D)

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.